|Positive Phase 2 Results in Medicinova's 2 Asthma Studies; Sequenom's Genetic Test Predicts Progression Risk|
|By Staff and Wire Reports|
|Monday, 12 November 2012 20:04|
MediciNova, Inc. (Nasdaq: MNOV) a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma.
The publication is entitled, "Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta(2)-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion" and is available online.
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator, and developer of high-quality, sustainable real estate for the broad and diverse science industry, is pleased to announce a 10-year lease transaction with Genomatica, Inc., the rising star of the industrial biotechnology sector.
Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that Dr. Chris Anzalone, President and Chief Executive Officer, will present a corporate overview at the 18th annual BIO-Europe international partnering conference on Tuesday, November 13th at 3:30 pm in Hamburg, Germany.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Tuesday, December 4, 2012 in New York City beginning at 8:00 am EST.
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations.
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports that the Company has signed an agreement with a European Union (EU) clinical site for a Proof-of-Concept (PoC) trial of Prurisol™, the Company's lead drug candidate for the treatment of psoriasis.
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced the successful completion of the transaction with Cordlife Group Limited (CLGL.SP) ("Cordlife"), a cord blood and tissue banking service provider listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). The transaction was first announced on August 15, 2012.
Cytori Therapeutics (NASDAQ: CYTX) announced this morning that a peer-reviewed case series using Cytori’s cell therapy to treat patients suffering from complex cryptoglandular fistula has been published in the current issue of the British Medical Journal: Case Reports.
DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it will present at the New York Society of Security Analysts' 16th Annual Investing in Life Sciences conference on Thursday, November 29. DARA recently launched its second product in five months (Soltamox®, the only FDA-approved oral liquid version of tamoxifen citrate), and is planning a third product launch for first quarter of 2013.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will lead a discussion, which may involve recent business developments and financial results, at the 24th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2012 at 2:00 PM Eastern.
Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease (AASLD) Annual Meeting in Boston, MA.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company developing Toll-like receptor (TLR) targeted product candidates for the treatment of autoimmune diseases and as vaccine adjuvants, today reported its financial results and business highlights for the third quarter ended September 30, 2012.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced it has raised $7.0 million in a private placement financing of convertible preferred stock and warrants.
Illumina, Inc. (NASDAQ:ILMN) today announced that VWR International, LLC, a global distributor of laboratory supplies and services, will distribute Illumina’s qPCR portfolio including the Eco™ Real-Time PCR System and NuPCR™ reagents within the United States, one of the world’s largest qPCR instrumentation markets.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new data from its completed Phase 1 study of IPI-145, the company’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) today announced the appointment of Mr. Kirk Look to the role of Chief Financial Officer.
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.
Pharmos Corporation (OTCQB: PARS) today announced that an abstract of the successful Duke clinical trial results was accepted and presented at the American College of Rheumatology (ACR) in Washington DC.
Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative microsurgical devices for ophthalmic and neurosurgical applications, today announced its upcoming participation in the Stephens Fall Investment Conference on Wednesday, November 14, 2012, at The New York Palace Hotel, New York.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR LLC to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile(C. diff)infection, the leading cause of hospital acquired infections (HAI), that may occur secondary to treatment with antibiotics.
VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) is excited to announce the installation of its VMS™ heart analysis system in Krankenhaus der Elisabethinen Hospital in Linz, Austria, University Medical Center Utrecht, The Netherlands and the German Heart Institute Berlin, Germany.
Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported financial and operational results for the third quarter ended September 30, 2012.